OPTIMUM PHENYTOIN-DOSAGE REGIMENS

被引：0
作者：
LUDDEN, TM
HAWKINS, DW
ALLEN, JP
HOFFMAN, SF
机构：
[1] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[2] UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78205
来源：
LANCET | 1976年 / 1卷 / 7954期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：307 / 308
页数：2
相关论文
共 50 条
  • [41] PHENYTOIN DOSAGE PREDICTIONS IN PEDIATRIC-PATIENTS
    YUEN, GJ
    LATIMER, PT
    LITTLEFIELD, LC
    MACKEY, RW
    CLINICAL PHARMACOKINETICS, 1989, 16 (04) : 254 - 260
  • [42] DOSAGE REGIMENS FOR STREPTOKINASE TREATMENT - EVALUATION OF A STANDARD DOSAGE SCHEDULE
    HIRSH, J
    AUSTRALASIAN ANNALS OF MEDICINE, 1970, 19 : 12 - &
  • [43] NUCLEAR MAGNETIC-RESONANCE ANALYSIS OF PHENYTOIN AND SODIUM PHENYTOIN IN SOLID DOSAGE FORMS
    HANNA, GM
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1984, 10 (03) : 341 - 354
  • [44] Optimum dosage regimen of palivizumab?
    Zaaijer, HL
    Vandenbroucke-Grauls, CMJE
    Franssen, EJF
    THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 444 - 445
  • [45] AN EFFICIENT CONTROL STRATEGY FOR DOSAGE REGIMENS
    HU, CP
    LOVEJOY, WS
    SHAFER, SL
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1994, 22 (01): : 73 - 94
  • [46] A COMPARISON OF 2 DOSAGE REGIMENS FOR VINCRISTINE
    CAREY, RW
    HALL, TC
    FINKEL, HE
    CANCER CHEMOTHERAPY REPORTS, 1963, (27): : 91 - 96
  • [47] PHARMACOKINETICS AND DOSAGE REGIMENS OF ANTIINFLAMMATORY DRUGS
    LEES, P
    MAY, SA
    WHITE, D
    ANNALES DE RECHERCHES VETERINAIRES, 1990, 21 : S73 - S78
  • [48] COST OF INDIVIDUALIZING AMINOGLYCOSIDE DOSAGE REGIMENS
    BOOTMAN, JL
    ZASKE, DE
    WERTHEIMER, AI
    ROWLAND, C
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1979, 36 (03): : 368 - 370
  • [49] ESTIMATING DRUG-DOSAGE REGIMENS
    DARRELL, JH
    WATERWORTH, PM
    MITCHISO.DA
    FOX, W
    ORR, JS
    SHIMMINS, J
    SPEIRS, CF
    LANCET, 1969, 2 (7629) : 1069 - +
  • [50] SYSTEMATICALLY INDIVIDUALIZING TOBRAMYCIN DOSAGE REGIMENS
    CIPOLLE, RJ
    SEIFERT, RD
    ZASKE, DE
    STRATE, RG
    JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 20 (10) : 570 - 580
12345